Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.39 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.38 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.38 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24386832 | 0.82 | ADORA2A (0.43) | SLC5A2ADORA2AADORA2BSLC29A1 | |
| SCHEMBL16310899 | 0.72 | SLC29A1 (0.47) | SLC5A2ADORA2AADORA2BSLC29A1SLC28A1 | |
| SCHEMBL21658577 | 0.72 | SLC29A1 (0.47) | SLC5A2ADORA2AADORA2BSLC29A1SLC28A1 | |
| SCHEMBL16311131 | 0.72 | SLC29A1 (0.47) | SLC5A2ADORA2AADORA2BSLC29A1SLC28A1 | |
| SCHEMBL19807415 | 0.72 | SLC29A1 (0.47) | SLC5A2ADORA2AADORA2BSLC29A1SLC28A1 | |
| SCHEMBL25612157 | 0.72 | SLC29A1 (0.47) | SLC5A2ADORA2AADORA2BSLC29A1SLC28A1 | |
| SCHEMBL31685710 | 0.71 | LMNA (0.42) | SLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL24983718 | 0.70 | CDA (0.48) | SLC29A1SLC28A1SLC28A2SLC28A3 | |
| SCHEMBL23719101 | 0.70 | SLC5A2 (0.46) | SLC5A2SLC5A1 | |
| SCHEMBL22933055 | 0.69 | SMN1; SMN2 (0.41) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | SLC5A2 228/4885ADORA2A 436/4885ADORA2B 152/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC5A2 228/4885ADORA2A 436/4885ADORA2B 152/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | SLC5A2 228/4885ADORA2A 436/4885ADORA2B 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.